Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese patients aged greater than or equal to 18 years old.~* Patient with a previous diagnosis of severe aplastic anemia and had insufficient response following at least one treatment course in the period time of \> 6 months of immunosuppression with a regimen containing anti-thymocyte globulin (ATG), anti-lymphocyte globulin (ALG), and/or cyclophosphamide, or alemtuzumab.~* Platelet count ≤ 30 × 10\^9/L at screening.~* Patient must not currently have the option of stem cell transplantation.~* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~* Patient with QTcF (Fridericia's QT correction formula) at screening \<450 msec, or \<480 msec with bundle branch block, as determined via the mean of a triplicate ECG and assessed at site.~Exclusion Criteria:~* Treatment with ATG/ALG, cyclophosphamide or alemtuzumab in the past 6 months.~* Congenital aplastic anemia~* AST or ALT ≥3 times the upper limit of normal.~* Creatinine, total bilirubin, and alkaline phosphatase (ALP) ≥ 1.5× local ULN (total bilirubin ≥ 2.5 × local ULN with Gilbert's Syndrome).~* Paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size determined by flow cytometry ≥ 50%.~* Presence of chromosomal aberration (-7/7q- detected by fluorescence in situ hybridization (FISH), or other aberrations detected by G-band staining).~* Evidence of a clonal hematologic bone marrow disorder on cytogenetics.~* Past medical history of thromboembolism within 6 months or current use of anticoagulants.~* Have any concomitant malignancies and must be fully recovered from treatment for any other malignancy and have been disease-free for 5 years.~* Patient with clinically significant.~* Patient with known hepatocellular disease~* Presences of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening.~* Cardiac disorder (NYHA) functional classification Grade II/III/IV~* Past medical history of immediate or delayed hypersensitivity to compounds chemically similar to eltrombopag or their excipients.~* Treatment with another investigational product within 30 days.~* Prior treatment with eltrombopag, romiplostim, or any other TPO (thrombopoietin) receptor agonist.~* Positive result for HIV (Human Immunodeficiency Virus) antibody test.~* Pregnant or nursing (lactating) woman.~* Woman of child-bearing potential.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Subjects will start eltrombopag treatment at 25 mg/day since Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).